Associated Genetic Biomarkers
DNA-damage-inducible transcript 3 (DDIT3) is a gene that encodes a transcription factor protein that functions as dominant negative inhibitor of DNA binding activity in C/EBP and liver activator proteins. Fusions, missense mutations, nonsense mutations, silent mutations, and frameshift deletions are observed in cancers such as intestinal cancer, lung cancer, and skin cancer.
DDIT3 is altered in 0.17% of all cancers.
The most common alterations in DDIT3 are DDIT3 Mutation (0.00%), DDIT3 R156C (0.00%), and DDIT3 S88T (0.00%) .
DDIT3 status serves as an inclusion eligibility criteria in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials that contain DDIT3 status as an inclusion criterion, 3 are phase 2 (3 open).
The most frequent alterations to serve as inclusion eligibility criteria are FUS-DDIT3 Fusion and DDIT3 Fusion .
Significance of DDIT3 in Diseases
Myxoid Liposarcoma +
DDIT3 is an inclusion criterion in 2 clinical trials for myxoid liposarcoma, of which 2 are open and 0 are closed. Of the trials that contain DDIT3 status and myxoid liposarcoma as inclusion criteria, 2 are phase 2 (2 open) .
DDIT3 is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains DDIT3 status and liposarcoma as inclusion criteria, 1 is phase 2 (1 open) .
Round Cell Liposarcoma +
DDIT3 is an inclusion criterion in 1 clinical trial for round cell liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains DDIT3 status and round cell liposarcoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.